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(Correspondence should be addressed to M-L Jaffrain-Rea; Email: jaffrain.ml@libero.it)AbstractGermline mutations of the aryl hydrocarbon receptor (AHR)-interacting protein (AIP) gene confer a
predisposition to pituitary adenomas (PA), usually in the setting of familial isolated PA. To provide
further insights into the possible role of AIP in pituitary tumour pathogenesis, the expression of AIP
and AHR was determined by real-time RT-PCR and/or immunohistochemistry (IHC) in a large
series of PA (nZ103), including 17 with AIP mutations (AIPmut). Variable levels of AIP and AHR
transcripts were detected in all PA, with a low AHR expression (P!0.0001 versus AIP).
Cytoplasmic AIP and AHR were detected by IHC in 84.0 and 38.6% of PA respectively, and
significantly correlated with each other (PZ0.006). Nuclear AHR was detected in a minority of PA
(19.7%). The highest AIP expression was observed in somatotrophinomas and non-secreting
(NS) PA, and multivariate analysis in somatotrophinomas showed a significantly lower AIP
immunostaining in invasive versus non-invasive cases (PZ0.019). AIP expression was commonly
low in other secreting PA. AIP immunostaining was abolished in a minority of AIPmut PA, with a
frequent loss of cytoplasmic AHR and no evidence of nuclear AHR. In contrast, AIP
overexpression in a subset of NS PA could be accompanied by nuclear AHR immunopositivity.
We conclude that down-regulation of AIP and AHR may be involved in the aggressiveness of
somatotrophinomas. Overall, IHC is a poorly sensitive tool for the screening of AIP mutations.
Data obtained on AHR expression suggest that AHR signalling may be differentially affected
according to PA phenotype.Endocrine-Related Cancer (2009) 16 1029–1043Endocrine-Related Cancer (2009) 16 1029–1043
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Introduction
Germline mutations of the aryl hydrocarbon receptor
(AHR)-interacting protein (AIP) gene confer a predis-
position to pituitary adenomas (PA; Vierimaa et al.
2006), usually in the setting of familial isolated PA
(FIPA; Daly et al. 2006, 2007, Beckers & Daly 2007).
Because mutations are likely to be inactivating and
associated with tumour loss of heterozygosity (LOH),
AIP is viewed as a new pituitary tumour suppressor gene
in 11q13 (Vierimaa et al. 2006). Most PA associated
with AIP mutations (AIPmut) are somatotrophinomas or
prolactinomas – although non-secreting (NS) adenomas
occur occasionally (Buchbinder et al. 2008). The
prevalence of AIP mutations in FIPA is 15% overall,
but reaches 50% in FIPA kindreds with homogeneous
somatotrophinomas (Vierimaa et al. 2006, Daly et al.
2007). AIPmut PA occur earlier than their sporadic
counterpart and are usually more aggressive (Beckers &
Daly 2007, Daly et al. 2007). Immunohistochemistry
(IHC) has shown AIP to be expressed by PA, with loss
of AIP staining in AIPmut tumours being variably
appreciated (Vierimaa et al. 2006, Georgitsi et al. 2007,
Leontiou et al. 2008). As such, the clinical application
of IHC for AIP as a screening tool remains con-
troversial. Germline AIP mutations are very rare in
patients with sporadic PA, although they can be
encountered in young acromegalics (Barlier et al.
2007, Cazabat et al. 2007, Iwata et al. 2007, Georgitsi
et al. 2008a). In addition, although variations in AIP
expression among sporadic PA have been recently
reported according to their functional phenotype
(Leontiou et al. 2008), their potential relationship with
tumour-evolutive features has not been investigated.
Thus, the possible role of AIP in PA pathogenesis
independently of germline mutations is unknown.
The best characterized function of AIP is to stabilize
the AHR, or dioxin receptor, in a cytoplasmic core
complex involving AIP, AHR and the heat shock
protein Hsp90. Upon activation, AHR moves to the
nucleus and heterodimerizes with the Ah receptor
nuclear translocator (ARNT) to exert direct transcrip-
tional effects (Petrulis & Perdew 2002). AHR is widely
expressed in endocrine tissues, and dioxin-related
compounds are endocrine disruptors (Pitt et al. 2000,
Nishimura et al. 2002, Pocar et al. 2005). In vitro
exposure to 2,3,7,8 tetrachlorodibenzo-p-dioxin
induces GH and prolactin (PRL) secretion from
rainbow trout pituitary cells, in part through AHR-
mediated transcriptional effects (Elango et al. 2006).
AIP generally enhances AHR response to exogenous
ligands by increasing its cytoplasmic levels, but
nuclear localization of non-ligand-bound AHR can be1030observed in the absence of AIP (LaPres et al. 2000).
This may be relevant to AIP-related tumourigenesis,
since endogenous functions of AHR are being
increasingly recognized (Barouki et al. 2007, Nguyen
& Bradfield 2008). AHR exerts complex modulatory
effects on cell cycle regulation and apoptosis (Marlowe
& Puga 2005), and genetic models have clearly
underscored its involvement in normal ontogeny and
in tumourigenesis (Gasiewicz et al. 2008). Dioxin is
carcinogenic (Popp et al. 2006), and AHR can be
overexpressed in human tumours (Harper et al. 2006,
Schlezinger et al. 2006). Yet, the effects of dioxin
exposure on the incidence of pituitary tumours remain
uncertain (Pesatori et al. 2008), and the expression of
AHR in the normal human pituitary and in PA has not
been reported to date.
We wished to further characterize AIP expression and
assess AHR expression and cellular localization in a
representative series of PA. We also aimed to further
characterize AIPmut PA in order to provide new insights
into their pathogenesis and possibly help identify patients
who could benefit from AIP mutational screening.Material and methods
Patients and samples
A series of 103 PA have been studied for AIP and AHR
expression by real-time RT-PCR (nZ66) and/or IHC
(nZ94). There were 46 GH-, 22 PRL-, 7 ACTH-,
2 TSH-secreting and 26 NS adenomas respectively.
Unselected sporadic adenomas were operated on for
medical reasons at the Neuromed Institute (Italy).
Seventeen FIPA samples were collected in 14 FIPA
patients who came from eight international centres
(Italy, Belgium, France, Brazil, Spain and Bulgaria),
out of which 10 PA were operated on in 8 patients with
a germline AIP mutation. The study was approved by
local ethical committees. Clinical, biological and
neuroradiological data, as well as intra-operative
findings and pre-operative pharmacological treatment,
were systematically recorded. Invasiveness was
defined according to pre-operative neuroradiological
imaging and intra-operative findings, including macro-
scopic evidence of dural infiltration. Tumour pheno-
type was defined on the basis of pre-operative
endocrine evaluation and immunohistochemical
characterization of hormone secretion. This latter was
available in all but two cases and performed with the
commercial anti-PRL, anti-GH, anti-FSH, anti-LH,
anti-ACTH and anti-TSH antibodies in use in the
participating centres (in Italy, polyclonal antibodies
from Orthodiagnostic Systems, Raritan, NJ, USA).www.endocrinology-journals.org
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Cell proliferation was evaluated in 77 PA by Ki-67
immunostaining with the monoclonal MIB-1 antibody
(DBA Italia srl, Milan, Italy), as previously described
(Jaffrain-Rea et al. 2002). Tumours showing micro-
scopic evidence of contamination by normal pituitary
fragments were considered for immunohistochemical
studies only. In addition, normal human pituitary
glands were collected at autopsy in four patients who
died from non-endocrine diseases and divided into
frozen and formalin-fixed paraffin-embedded frag-
ments, as previously described (Fratticci et al. 2007).Figure 1 AIP and AHR gene expression in pituitary adenomas
according to tumour phenotype box plots representing AIP/b-
actin and AHR/b-actin mRNA ratios in all prolactinomas (PRL),
somatotrophinomas (GH), non-secreting adenomas (NS),
corticotrophinomas (ACTH), thyrotroph adenomas (TSH) and in
normal pituitary samples (NP) are shown in panels A and B
respectively (note the different scales used).Molecular and genetic analysis
Methodological details on RT-PCR and real-time
RT-PCR protocols are provided in the Supplementary
Materials and methods, which can be viewed online at
http://erc.endocrinology-journals.org/supplemental/.
Briefly, after preliminary, RT-PCR experiments
allowed the exclusion of tumour samples with potential
contamination with normal pituitary cells according to
cell-specific transcription factors’ criteria and revealed
an almost universal AIP and AHR gene expression; AIP
and AHR transcripts were quantified by real-time
RT-PCR based on a Taqman methodology and
corrected for b-actin expression. Leukocyte genomic
AIP sequencing (gDNA) was performed in 28 patients,
as previously described (Daly et al. 2007). Searches for
somatic mutations, or LOH in AIPmut tumours, were
performed by direct sequencing of tumour cDNA and/
or DNA (tDNA) in 35 and 6 cases respectively.
Procedures for AIP cDNA sequencing are described in
the electronic Supplementary Materials and methods.
Overall, the AIP gene status could be determined in 67
cases. Wherever new changes in AIP sequencing were
identified, AIP variations were considered as AIP
mutations for statistical purposes and their potential
biological significance further analysed in the
Supplementary Materials and methods and in the
Discussion section.Immunohistochemistry
Tissue sections were dewaxed in xylene and
rehydrated through a descending ethanol series, and
antigen retrieval was performed by microwave
boiling at 850 W in citrate buffer 0.1 M, pH 6.0.
Mouse monoclonal antibodies directed against AIP
(clone 35-2) and AHR (clone RPT9, referred to as
‘N-mAb’) were purchased from Novus (Novus
Biologicals LLC, Littleton, CO, USA) and both used
at a 1:500 dilution, in 94 and 83 PA respectively.
A polyclonal rabbit anti-AHR antibody was also usedwww.endocrinology-journals.orgin 61 PA (17 PRL-, 21 GH-, 3 ACTH-secreting and
20 NS respectively) at a 1:50 dilution (sc-5579,
referred to as ‘C-pAb’, Santa Cruz Biotechnology,
Santa Cruz, CA, USA). This antibody proved to be
more sensitive than the N-mAb in the detection of
nuclear AHR in positive control sections (human
invasive breast cancer samples and rat liver), and
cytoplasmic background could be reduced by
introducing a further blocking step with 5% milk in
PBS. IHC was performed with a multilink biotinylated
antibody and the avidin–biotin peroxidase system
according to the manufacturer’s instructions
(LSABC kit, DAKO Cytomation, Milan, Italy).
Negative controls were performed omitting the
primary antibody. Topographical localization of AIP-





Table 1 Aryl hydrocarbon receptor-interacting protein (AIP) expression in the whole series of pituitary adenomas (PA) according to patients and tumours characteristics
Age (years) Pre-operative treatment Invasiveness SSE




0.8G0.9 0.3G0.4 0.9G1.0 0.015 N/A – 0.5G0.7 1.0G1.0 0.0197 0.7G0.5 0.9G1.1 NS
AIP staining
(94)
37/94 11/32 26/62 NS – 14/52 22/41 0.0090 20/63 17/31 0.031




0.9G0.9 0.5G0.6 1.0G1.0 NS 0.8G0.9 1.0G1.0 NS 0.3G0.2 1.1G1.0 0.039 0.8G0.6 0.9G1.1 NS
AIP staining
(44)
23/44 9/19 14/25 NS 12/19 11/25 NS 6/22 17/22 0.0009 8/25 15/19 0.002




0.5G0.5 0.1G0.1 0.6G0.5 NS 0.3G0.3 0.6G0.7 NS 0.4G0.3 1.0G0.9 NS 0.5G0.5 – NS
AIP staining
(21)
3/21 1/8 2/13 NS 1/7 2/14 NS 3/15 0/6 NS 3/16 0/5 NS




1.0G1.3 0.3G0.1 1.0G1.3 NS N/A – 0.7G1.0 1.0G1.0 NS 1.0G1.03 0.6 –
AIP staining
(21)
9/21 1/3 8/17 NS – 5/14 3/6 NS 9/19 0/1 NS




0.7G0.3 0.4 0.7G0.3 – N/A – 0.4 0.7G0.3 – 0.4G0.1 0.8G0.3 NS
AIP staining (6) 1/6 0/1 1/5 – – 0/1 1/5 – 0/2 1/4 NS




0.2G0.1 0.3 0.1 – 0.2G0.1 – – – 0.2G0.1 – – 0.2G0.1 –
AIP staining (2) 0/2 0/1 0/1 0/2 – – – 0/2 – 0/2 –
– – – – – –
For raw data, the number of studied cases is indicated within brackets. The AIP/b-actin ratio was defined according to real-time RT-PCR experiments. AIP staining refers to significant





























































Figure 2 AIP and AHR immunostaining in pituitary adenomas (PA), excluding AIPmut PA. Shown are representative examples
of AIP and AHR immunostaining in different pituitary adenomas (PA), excluding AIPmut PA. For each image, the PA endocrine
phenotype is indicated in the upper right corner, the corresponding antibody in the bottom left corner and magnification in the
bottom right corner respectively. AIP immunostaining was quoted CC in a somatotrophinoma, C in a non-secreting PA and
C/K in a prolactinoma (A, B and C respectively). An example of microprolactinoma displaying AIP and AHR down-regulation
(quoted C/K) as compared with the adjacent normal pituitary (indicated as NP) is shown in D and E respectively; nuclear
AHR staining in this case was observed in the normal pituitary, but not in adenoma cells (F). Most PA had no or weak AHR
immunoreactivity (G and H respectively), a few cases displaying nuclear immunostaining, including a non-secreting FIPA
without AIP mutation (I).
Endocrine-Related Cancer (2009) 16 1029–1043using pre-diluted mouse mAbs for pituitary hormones
(DAKO Cytomation). Semi-quantitative analysis of
cytoplasmic AIP and AHR immunostaining was
performed at 20! and 40! magnifications and
semiquantitatively scored as follows: K (negative);
C/K (weak immunostaining and/or scattered
positive cells);C (diffuse, moderate immunostaining);
CC (diffuse, strong immunostaining). In the presence
of heterogeneous staining, the areas obtaining the
highest score were considered for statistical purposes.
Nuclear staining for AHR (C-pAb) was further
evaluated at high magnification (100!) in all cases.
A double step immunohistochemical study was also
performed as previously described (Fratticci et al.
2007) to first detect cytoplasmic AIP or the pituitary
hormones GH, PRL, ACTH and FSH respectively
using 3-3 0-diaminobenzidine (DAB) as a chromogen,
followed by a second step for the detection of nuclear
AHR (C-pAb) using Novored as a chromogen (Vector,
DBA Italia), introducing a further blocking step withwww.endocrinology-journals.orgmilk as indicated hitherto. Photographs of slides were
taken using a Zeiss Axioplan 2 microscope and a Leica
DFC 320 digital camera.Statistical analysis
All data are expressed in meanGS.D. and statistical
analyses were performed using Statview 5.01 soft-
ware for PC (SAS Institute, Cary, NC, USA).
Continuous values were analysed by non-parametric
analysis, using Mann–Whitney and Kruskal–Wallis
test for 2 and R3 group comparisons respectively
and the Spearman test for correlation studies.
Distribution of nominal values was compared by the
c2-test, logistic regression being used for multivariate
analysis. For logistic regression and analysis of
subgroups, the immunostaining scores for cyto-
plasmic AIP and AHR were transformed into binary
parameters as follows: significant (scoresC andCC)


































































R304X Italy F 21 Amenorrhoea, weight
gain, mild acrome-












C/K CK N ND





















C/K CK N ND
Fam 1C
TS



















































































None See values at
diagnosis
FSH, LH C CK NK
Fam 3B
TS
















































































































Het C,C/K CC/K NK
Spor 1
TS














C CK N ND
Spor 2
TS




















































HetC/K,K CC/K N ND





N/A None (RxT) GH 42.3,
IGF-I [,
PRL 60






















































a(i)Previously reported in Daly et al. (2007), (ii)clinical details on Fam1 A and B previously reported in Ferretti et al. (2001), (iii)previously reported in details in Naves et al. (2007),
(T) only tumour available.
bDH, definitive height.
cMa, macroadenoma; SSE, suprasellar extension; maximal tumour diameter within brackets; InvK, non-invasive; InvC, invasive; CS, cavernous sinus.
dAIP staining with semi-quantitative score.CC strong, diffuse; C moderate, diffuse; C/K weak or scattered positive cells;K negative.





























































Table 3 Characteristics of somatotrophinomas and relationship with the presence of aryl hydrocarbon receptor-interacting protein
(AIP) mutations
Group A Group B P
Patients
Age 18.7G6.6 40.1G12.5 P!0.0001
Sex 7M/5F 13M/17F NS
Tumours
Suprasellar extension 10/14 (71.4%) 16/32 (50.0%) NS
Invasive 10/14 (71.4%) 12/32 (37.5%) c2Z4.49, PZ0.034
Ki-67, O3.0% 5/11 (45.4%) 6/29 (20.7%) NS
Pre-operative treatment 7/14 (50.0%) 13/32 (40.6%) NS
AIP expression
AIP/b-actin mRNA (n) 0.18G0.05 (4) 1.05G0.98 (16) PZ0.072
AIP score (K;C/K;C;CC) 2;8;3;1 1;10;15;4 NS
Low AIP score (C/K,K) 10/14 (71.4%) 11/30 (36.7%) c2Z4.62, PZ0.031
AHR expression
AHR/b-actin mRNA (n) 0.01G0.02 (4) 0.02G0.03 (16) NS
AHR score (N-mAb) (K;G;C) 10;2;0 15;12;2 NS
Detectable AHR (N-mAb) (C/K,C) 2/12 (16.7%) 14/29 (48.3%) c2Z3.56, PZ0.059
Nuclear AHR (C-pAb) 0/7 2/13 NS
Groups A and B refer to patients and tumours with or without documented AIP mutations respectively. AIP/b-actin and AHR/b-actin
mRNA ratios were obtained by real-time RT-PCR (the number of studied tumours is indicated in italicized text within brackets).
Semi-quantitative AIP and AHR scores were defined by immunohistochemistry (CC diffuse, strong;C diffuse, moderate;C/K
weak immunostaining and/or scattered positive cells;K negative), using anti-AIP and AHR (N-mAb) monoclonal antibodies and, in a
subset of cases, a polyclonal anti-AHR antibody (C-pAb) recognizing the C-terminal half of AHR respectively. Nearly significant P
values are indicated in italics; NS, non-significant.
M-L Jaffrain-Rea et al.: AHR and AIP in pituitary adenomasdetectable (scores C/K and C) versus undetectable
AHR immunostaining respectively. The level of
significance was set at P!0.05.Results
Normal pituitary
AIP and AHR transcripts were detected in normal
pituitary samples, with a significantly lower expression
of AHR (P!0.0001 versus AIP). Accordingly, AIP-
immunopositive cells were largely present in the
adenohypophysis (see Supplementary Fig. 1A, which
can be viewed online at http://erc.endocrinology-
journals.org/supplemental/), with topographical
studies arguing for a preferential strong and diffuse
expression in somatotrophs (see Supplementary
Fig. 1B), and to a lesser extent by lactotrophs (data
not shown). AHR (N-mAb) immunostaining was less
intense, with a roughly similar, although more
scattered and diffuse, cell distribution (see Supple-
mentary Fig. 1C). AIP and AHR (N-mAb) immunos-
taining was confined to the cytoplasm (see
Supplementary Fig. 1D and E), although some degree
of AHR nuclear positivity was revealed by C-pAb
immunostaining (see Supplementary Fig. 1F). Some
scattered AIP- and AHR-immunopositive cells
were observed in the pars intermedia, containing1036ACTH-secreting cells (see Supplementary Fig. 1G–I).
Double immunostaining with AHR C-pAb revealed
co-localization of AHR with AIP (see Supplementary
Fig. 1J), nuclear AHR immunostaining being observed
in a subset of somatotrophs (see Supplementary
Fig. 1K) and a few corticotrophs (data not
shown), whereas in lactotrophs, AHR appeared to be
mostly perinuclear (see Supplementary Fig. 1L).
FSH-secreting cells were virtually negative for nuclear
AHR (data not shown).Pituitary adenomas
The expression of AIP and AHR has been first
performed on the entire series of PA. AIP and AHR
transcripts were detected in all PA (Fig. 1), with a
markedly lower AHR expression (P!0.0001 versus
AIP). Accordingly, AIP and AHR proteins were
detected in 84.0 and 38.6% of the cases respectively.
Marked individual variations were observed in AIP
gene expression and immunostaining (Fig. 1A;
Table 1) – examples of IHC scoring are shown in
Fig. 2A–C, including one microprolactinoma with a
normal pituitary fragment shown as an internal
control (Fig. 2D). The AIP immunostaining score
was significantly correlated with AIP expression
(PZ0.0014) and with the AHR (N-mAb) score
(c2Z18.1, PZ0.006). However, cytoplasmic AHRwww.endocrinology-journals.org
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Figure 3 AIP and AHR immunostaining in AIPmut pituitary adenomas. Examples of AIP and AHR immunostaining and relative semi-
quantitative AIP evaluation in AIPmut PA with references to Table 2 for case identification. (A) AIP immunostaining in a familial
somatotrophinoma (Fam 1A) with a R304X mutation (C/K, an area displaying scattered positive cells), with no detectable AHR in
the cytoplasm (B) or in the nucleus (C). (D) AIP immunostaining (C) in a familial somatotrophinoma (Fam 4) with an E174fsX21
mutation. (E) Low AIP immunostaining (C/K) and (F) lack of detectable AHR immunostaining in a sporadic somatotrophinoma with
a germline A277P mutation (Spor2). (G) Negative AIP immunostaining in a sporadic somatotrophinoma with a Q82fsX7 mutation.
Differential expression of AIP in two siblings (Fam 3) with a K241E mutation, affected by a prolactinoma (H) (quotedK) and a NS
adenoma (I) (quotedC) respectively.
Endocrine-Related Cancer (2009) 16 1029–1043immunostaining (N-mAb) was generally weak, and
nuclear immunostaining (C-pAb) was observed in a
minority of cases (12/61Z19.7%; Fig. 2E–I),
including a familial NS PA with normal AIP
sequencing (Fig. 2I).
Correlation with clinical characteristics
A series of factors were found to account for the
variations in AIP mRNA and AIP immunostaining
observed on the entire series of PA, including tumour
phenotype and aggressiveness (Table 1). Briefly, both
were found to be highly variable in somatotrophino-
mas, generally low in prolactinomas and in other
secreting PA, but paradoxically high in a subset of NS
adenomas (Fig. 1A; Table 1). AIP mRNA was
significantly lower in invasive PA (PZ0.0197 versus
non-invasive), which were also more likely to show a
low AIP immunostaining (c2Z6.91, PZ0.009 versus
non-invasive). Overall, no significant difference in AIP
expression was observed according to the AIP gene
status (data not shown). AHR mRNA was poorlywww.endocrinology-journals.orginfluenced by phenotype (Fig. 1B), but complete loss
of AHR immunostaining (N-mAb) was significantly
more frequent in invasive (71.4 vs 47.4% in non-
invasive, c2Z5.2, PZ0.022) and in AIPmut PA (86.7
vs 58.7% in non-mutated PA, c2Z3.92, PZ0.048).
Nuclear AHR immunostaining (C-pAb) was observed
in three somatotrophinomas, three prolactinomas and
six NS adenomas respectively, but in none of the
AIPmut PA included in this study.Analysis of PA subgroups
Because the proportion of AIPmut tumours varied
according to phenotype, data obtained in all somato-
trophinomas, prolactinomas and NS adenomas have
been further analysed as distinct subgroups.Somatotrophinomas
As most AIPmut tumours were somatotrophinomas,
data were analysed according to the presence (group A)
or the absence (group B) of documented AIP mutations1037
AUTHOR COPY ONLYM-L Jaffrain-Rea et al.: AHR and AIP in pituitary adenomas
respectively. In group A, AIP mutations were identified
on patient’s leukocyte DNA in six FIPA patients (eight
PA) and in five sporadic cases, respectively, and on
tumour cDNA and DNA in an additional sporadic case
where no leukocyte DNA was available. Individual
data are shown in Table 2 (Family 1, 2 and 4; Spor 2–6
and 8). Germline mutations were heterozygous
whereas only the mutated allele was detected in
cDNA/tDNA where available, thereby indicating
somatic loss of heterozygosity in four out of five
cases (Fam 1B and C, Fam 2B; Spor 2) and strongly
suggesting hemizygosity in the other case (Spor 8). In
group B, the lack of detectable AIP mutations was
confirmed in most cases by sequencing of gDNA
(nZ7), tumour cDNA (nZ12) and/or tDNA (nZ4)
respectively. Data observed in group A and group B are
summarized in Table 3. Somatotrophinomas occurred
in group A at a significantly younger age (P!0.0001)
were more frequently invasive (PZ0.034) and more
likely to display decreased AIP immunostaining
(PZ0.031) than those in group B respectively. Of
note, the pattern of AIP immunostaining could differ
according to the mutation (Fig. 3A, D, E and G).
Similarly, there was a trend towards cytoplasmic AHR
(N-mAb) being less likely to be detected in group A
(Fig. 3B and F) than in group B (PZ0.059). Further
evaluation with the AHR C-pAb confirmed the lack of
nuclear immunostaining in group A (Fig. 3C).
Excluding somatotrophinomas with undetermined
AIP gene status, AIP mutations were estimated to
account for AIP gene down-regulation in 3 out of
4 cases and for low AIP immunostaining in 10 out of
19 cases respectively. Low AIP immunostaining
tended to be more frequent in AIPmut somatotro-
phinomas than in those with normal AIP sequencing
(10 out of 14 vs 9 out of 22, c2Z3.20, PZ0.074),
indicating a sensitivity of IHC in detecting AIP
mutations of 71.4% and a specificity of 40.9%
respectively. According to logistic regression analysis,
tumour invasiveness was the only independent
predictor of AIP down-regulation in somatotrophino-
mas (PZ0.019), whereas young age was the only
independent predictor of AIP mutations (PZ0.002; see
Supplementary Table 2, which can be viewed online at
http://erc.endocrinology-journals.org/supplemental/).
Complete loss of AHR (N-mAb) immunostaining was
significantly more frequent in invasive than in non-
invasive somatotrophinomas (78.9 vs 35.7%, c2Z4.7,
PZ0.012), while a trend was confirmed in AIPmut
somatotrophinomas as compared with those with
normal AIP sequencing (83.3 vs 52.4.%, c2Z2.76,
PZ0.096).1038Prolactinomas
Both AIP mRNA and AIP immunostaining were
generally low in prolactinomas (Table 1; Figs 1 and
2C and E). The AIP gene status was available in most
cases (15 out of 22), according to AIP sequencing
performed on gDNA (nZ8) or tumour cDNA (nZ7).
Germline AIP mutations were identified in three cases
(Table 2, Fam 3B; Spor 1 and 7), although no splicing
alteration was found by tumour cDNA sequencing in
Spor 7. Low AIP immunostaining occurred in pro-
lactinomas with normal AIP sequencing (10 out of 12)
as well as in AIPmut (2 out of 3). Excluding AIPmut
tumours, low AIP immunostaining was confirmed to
be significantly more frequent in prolactinomas than
in somatotrophinomas (c2Z16.5, PZ0.0009). Cyto-
plasmic (N-mAb) and nuclear (C-pAb) AHR immuno-
staining could be detected in 11 out of 21 (52.3%)
and 3 out of 17 (17.6%) prolactinomas respectively.
NS adenomas
The mean AIP mRNA in NS adenomas was similar to
that observed in somatotrophinomas, 42.3% of PA in
this group also displaying significant AIP immuno-
staining (Table 1; Figs 1 and 2B). A germline AIP
mutation was identified in one FIPA patient (Table 2,
Fam 3A), and normal AIP sequencing was documented
in 11 cases on tumour cDNA (nZ8) or tDNA (nZ3) –
including all NS occurring in patients aged%50 years
old. Surprisingly, a significant AIP immunostaining
was observed in the AIPmut NS adenoma (Fig. 3I), but
not in the prolactinoma that was surgically resected
in her brother (Fig. 3H). AIP immunostaining was
frequently associated with nuclear AHR (55.5 vs 9.0%
according to the presence or the absence of significant
AIP respectively, c2Z5.09, PZ0.02), which in turn
was significantly correlated with cytoplasmic AHR
(c2Z11.6, PZ0.0007). No significant correlation was
found between AIP and AHR immunostaining and
tumour volume, invasiveness or immunostaining for
gonadotrophins.Discussion
This study shows for the first time that both AHR and
AIP are expressed in the normal human pituitary and
frequently down-regulated in PA. In normal pituitaries,
topographical studies indicated a preferential
expression of AIP by somatotrophs, which display a
strong and diffuse expression, and to a lesser extent by
lactotrophs. These findings are in agreement with
recent work by Leontiou et al. (2008), which also
localized AIP within GH and PRL-containingwww.endocrinology-journals.org
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secretory granules in normal cells. Scattered AIP-
expressing cells were also observed in the
pars intermedia. AHR was expressed at lower
transcriptional levels and with a lower immunostaining
intensity than AIP, with scattered AHR-expressing
cells being more widely distributed than AIP-
expressing cells. AIP and AHR were first observed in
the cytoplasm only. However, further evaluation with
an antibody directed against the C-terminal part of the
AHR protein revealed moderate nuclear immunostain-
ing in a subset of somatotrophs and in some
corticotrophs. Differences between cytoplasmic and
nuclear staining may reflect variations in protein–
protein interactions involving AHR in subcellular
compartments, which may in turn influence epitope
recognition and modify the sensitivity of the
corresponding IHC assays. As DNA binding and
basic-helix-loop-helix (bHLH) -interacting domains
of AHR are located N-terminal (Fukunaga et al. 1995,
Fukunaga & Hankinson 1996), the N-mAb epitope of
AHR may be masqueraded in its transcriptionally
active conformation. Thus, nuclear immunostaining
with the C-terminal antibody alone may indicate some
degree of endogenous AHR activity. Supporting a role
for AHR in pituitary development and/or cell differ-
entiation, binding sites for the pituitary transcription
factors Lhx3 and Pit-1 are present in the promoter of
the AHR gene (Harper et al. 2006). Constitutive ex-
pression of AHR and ARNT has been shown in the rat
hypothalamus (Korkalainen et al. 2005). These data
suggest a physiological role for AHR in the human
hypothalamus–pituitary unit, further extending the
spectrum of bHLH transcription factors expressed in the
normal pituitary and PA (Jackson et al. 1993, Ferretti
et al. 2001, Huang et al. 2002, Fratticci et al. 2007).
In agreement with a recent report (Leontiou et al.
2008), AIP was found by real-time RT-PCR to be
expressed at a transcriptional level in all PA, with a
relative overexpression in a subset of somatotrophino-
mas and NS adenomas. Accordingly, significant AIP
immunostaining was observed in about half of
somatotrophinomas and NS adenomas, but in %15%
of other PA. Thus, AIP expression can be either
retained or down-regulated in somatotrophinomas and
is frequently decreased in prolactinomas, whereas
abnormal AIP expression may occur in a subset of
NS adenomas.
We first focused our attention on the significance of
AIP down-regulation in somatotrophinomas. In these
tumours, decreased gene and protein expression of AIP
were significantly associated with the presence of
aggressive features and, although AIP immunostaining
tended to be lower in AIPmut somatotrophinomas, onlywww.endocrinology-journals.orginvasiveness was an independent predictor of AIP loss.
On the other hand, young age (!30 years of age) was
an independent predictor for the presence of AIP
mutations, but not for low AIP immunostaining. These
findings may have interesting pathogenetic and clinical
implications. First, they strongly suggest that AIP
down-regulation may be involved in the progression of
somatotrophinomas, regardless of detectable germline
AIP mutations. Although we cannot exclude the
presence of large AIP genomic deletions, this is
unfrequent (Georgitsi et al. 2008b), and additional
mechanisms of AIP silencing may be present. Second,
such data contrast with those obtained in prolactino-
mas, where a low AIP expression could be observed at
early stages of the disease, suggesting a peculiar role
for AIP in somatotrophs. This could explain the large
predominance of somatotrophinomas among PA
developing in patients with germline AIP mutations,
as reported in this and other studies (Cazabat et al.
2007, Daly et al. 2007), and the frequent aggressive-
ness of AIPmut somatotrophinomas (Daly et al. 2007,
Iwata et al. 2007, Toledo et al. 2007, this study). This is
consistent with the high expression of AIP in normal
somatototrophs, and supported by functional experi-
ments on GH3 cells (Leontiou et al. 2008). Third, IHC
may not be as suitable as previously suggested for the
pre-screening of patients with germline AIP mutations
(Georgitsi et al. 2007). Indeed, our data support recent
evidence that AIP can frequently be detected in AIPmut
tumours (Leontiou et al. 2008). Such discrepancies
may depend on the type of mutation and, to a lesser
extent, antibody characteristics. Due to somatic
hemizygosity for the mutated AIP allele, as further
supported by cDNA sequencing in this study, IHC data
will depend on epitope expression by the mutated
protein, if actually transcribed. In fact, AIP immunos-
taining can theoretically be retained unless early stop
mutations are present. Early data on IHC were obtained
in series where Finnish patients and their distinctive
Q14X early stop mutation were largely represented
(Georgitsi et al. 2007). Although the AIP immunoscore
in AIPmut somatotrophinomas can also be low due to
mono-allelic gene expression, this is of limited
diagnostic interest, since semi-quantitative interpre-
tation of IHC is difficult to standardize and can be
confounded readily. Thus, evidence of AIP immunos-
taining should not discourage AIP gene sequencing in
acromegalics with a familial history of FIPA or a
young age at disease onset. Furthermore, IHC is
unsuitable as a pre-screening tool in prolactinomas,
due to the frequent loss of significant AIP immunos-
taining in this group.1039
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The familial AIP mutations reported herein (E174fs,
K241E, Q285fs and R304X) were previously published
(Daly et al. 2007, Naves et al. 2007), whereas seven
out of the eight nucleotide changes identified in
patients with sporadic PA were undescribed. They
consisted of one frameshift (Q82fs) and three missense
(R128H, V195A and A277P) mutations respectively,
three intronic changes (IVS2 c.279C23COT, IVS3
c.468C16 GOT and IVS3 c.468C15COT) being also
recognized. None was observed in controls and
comparison with available SNPs, and orthologue
sequences’ databases were performed (see the elec-
tronic Supplementary Materials and methods). Briefly,
the Q82fs frameshift mutation is expected to encode for
a truncated protein after seven amino acids. None of
the novel missense changes has been identified as a
SNP to date, the amino acid residues K(241), V(195)
and A(277) are highly conserved among species, and
loss of the wild-type allele could be verified by cDNA
sequencing in the latter case. In contrast, the presence
of an arginine or a histidine at position 128 variant
occurs variably across mammalian species and may
represent an unrecognized human polymorphism,
which might explain normal AIP immunostaining in
this case. However, the exclusion of this case from
AIPmut somatotrophinomas did not significantly alter
the statistical results obtained in this group (data not
shown). Of note, in the siblings affected by a K241E
mutation, AIP immunostaining was present in the NS
PA, but absent in the prolactinoma. This may reflect
the differential AIP expression in these two pheno-
types, regardless of the AIP mutation itself, which
should not affect the epitope recognized by the mAb
used in this study. The novel intronic changes, none of
them being encountered in controls, are not expected to
induce alterations in AIP splicing by in silico analysis,
and this was confirmed by cDNA sequencing in the
prolactinoma associated with a germline change in
intron 2. However, the contiguity of the two nucleotide
changes in intron 3 and the young age of the affected
patients, both with somatotrophinomas with a low or
heterogeneous AIP immunostaining, favour their
possible role in the onset of the disease and suggest
possible molecular implications of intronic changes
outside recognized splicing sites (Kleinjan & van
Heiningen 2005). The R304X mutation was identified
in an additional sporadic somatotrophinoma – a young
Italian patient unrelated to the family included in this
study, which was previously reported in detail (Ferretti
et al. 2001, Daly et al. 2007). This mutation has been
recurrently recognized in Europe (Vierimaa et al.
2006, Cazabat et al. 2007, Daly et al. 2007, Leontiou
et al. 2008), and R304Q mutations being occasionally1040reported also (Georgitsi et al. 2007, Leontiou et al.
2008). This reinforces the concept of codon 304 as a
relative ‘hot spot’ in the AIP gene, although some
founder effect concerning the R304X mutation cannot
be excluded. Of note, AIP was detected by IHC in
all R304X somatotrophinomas studied so far and,
where available, electron microscopy showed sparsely
granulated somatotrophinomas (Ferretti et al. 2001,
Leontiou et al. 2008).
Another major aim of this study was to investigate
for the first time the possible role of AHR in the
pathogenesis of PA, especially in AIPmut tumours. Low
levels of AHR transcripts were found in PA as well as
in normal pituitary samples. Cytoplasmic AHR
immunostaining was detected in 40.0% of PA, being
generally weaker in intensity as compared with normal
pituitaries, and significantly correlated with AIP
immunostaining. This is consistent with AHR destabi-
lization in the presence of low AIP levels, thereby
supporting a role for AIP in AHR cytoplasmic
stabilization in the human pituitary, as observed in
most tissues. In AIPmut PA, AHR can be further
destabilized by a defective interaction with the AIP
protein. As the C-terminal half of AIP is critical for
interaction with AHR, which is abolished by truncation
of the last five amino acids (Bell & Poland 2000), AIP-
truncating mutations are expected to prevent the
constitution of the cytoplasmic complex. The
functional implications of each missense mutation
would need specific in vitro experiments, but a number
of single amino acid changes occurring in the TPR
region can abolish AIP binding to hsp90 and/or
strongly reduce AIP/AHR interaction (Bell & Poland
2000, Petrulis & Perdew 2002). The N-terminal part of
AIP may also contribute to the cytoplasmic stabil-
ization of AHR (Kazlauskas et al. 2002). Accordingly,
none of the AIPmut PA showed nuclear AHR staining,
suggesting that increased AHR nuclear signalling is not
implicated in AIP-related tumourigenesis. Hence,
AHR down-regulation may be involved in AIPmut
and/or invasive somatotrophinomas, although we
cannot exclude a non-specific bystander effect of AIP
down-regulation. In contrast, AHR appears to be
up-regulated in a subset of NS overexpressing AIP.
Of note, NS but not GH-secreting PA have been
reported after Seveso’s exposure (Pesatori et al. 2008).
These findings suggest a differential role of AHR in
pituitary cells, and further in vitro investigations
should help clarifying these issues.
In addition to AHR modulation, AIP is known to
interact with a number of cytoplasmic proteins
including phosphodiesterases (Bolger et al. 2003,
de Oliveira et al. 2007), thereby possibly modulatingwww.endocrinology-journals.org
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cAMP concentration, survivin, an anti-apoptotic
protein (Kang & Altieri 2006), and Ret (Vargiolu
et al. 2009). Interactions with phosphodiesterases can
be altered by AIP mutations (Bolger et al. 2003,
de Oliveira et al. 2007). Possible alterations in cAMP
signalling or apoptosis accompanying down-regulation
of AIP in somatotrophinomas or increased AIP
expression in NS PA should be further investigated.
In conclusion, this study supports the role of AIP in
the cytoplasmic stabilization of AHR and shows that
reduced AIP and AHR expression are frequently
observed in PA, at least at a protein level, with the
exception of NS adenomas, in which up-regulation of
both proteins can be observed. It suggests a possible
role for AIP and AHR down-regulation in the
progression of somatotrophinomas, independently
from germline mutations, and indicates that IHC is
not a sufficiently sensitive tool for the detection of AIP
mutations in somatotrophinomas, and is unsuitable to
this purpose in prolactinomas or NS PA.Declaration of interest
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